NovAccess Global

XSNX

Biotechnology · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$6,165

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+256.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 5.8M (2019) → 20.8M (2023)

NovAccess Global Inc. is a small biotechnology company focused on developing treatments for mental health conditions, particularly depression and related disorders. Its main area of work involves ketamine-based therapies and related mental health clinic operations, targeting patients who have not responded well to standard treatments. The company operates in the broader mental health biotech space, which has seen growing interest as traditional antidepressants fail a large portion of patients.

NovAccess generates little to no revenue at this stage, as it is still in early development and building out its business model around clinic services and potential drug development. It operates primarily in the United States and carries a very small market capitalization, meaning it is considered a micro-cap or nano-cap stock. The company faces significant risks, including the need to raise additional cash to fund operations, heavy competition from larger and better-funded mental health companies, and an unproven path to consistent profitability.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+53.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$154,362/ year

↓ Declining (-17% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

57.3%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$794 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

NovAccess Global has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

-154.9%

Earnings shrinking (-154.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial